ELISA Kit for Interleukin 1 Receptor Antagonist (IL1RA)
IL1RN; IL1-RA; ICIL1RA; IL1ra3; IL1F3; IRAP;IL-1RA; Interleukin-1 Family Member 3; IL1 inhibitor; Anakinra
- Product No.SEA223Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range3.12-200pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 1.33pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 445
For more details, please contact local distributors! US$ 2003
For more details, please contact local distributors! US$ 3783
For more details, please contact local distributors! US$ 31150
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Interleukin 1 Receptor Antagonist (IL1RA).
No significant cross-reactivity or interference between Interleukin 1 Receptor Antagonist (IL1RA) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Interleukin 1 Receptor Antagonist (IL1RA) and the recovery rates were calculated by comparing the measured value to the expected amount of Interleukin 1 Receptor Antagonist (IL1RA) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Interleukin 1 Receptor Antagonist (IL1RA) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Interleukin 1 Receptor Antagonist (IL1RA) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Interleukin 1 Receptor Antagonist (IL1RA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
|The Veterinary Journal||Mucosal imbalance of interleukin-1β and interleukin-1 receptor antagonist in canine inflammatory bowel disease ScienceDirect: S1090023312000962|
|Daily quercetin supplementation over a period of two weeks results in a moderate accumulation of total plasma flavonols in horses Researchgate:Source|
|Journal of Equine Veterinary Science||Synovial Fluid and Serum Concentrations of Interleukin-1 Receptor Antagonist and Interleukin-1 Science: Article|
|Journal of Equine Veterinary Science||A Two-Week Quercetin Supplementation in Horses Results in Moderate Accumulation of Plasma Flavonol Concentrations Science: Article|
|Scientific publications in peer reviewed journals||Evidence-based review of efficacy and adverse effects of joint medication and evaluation of synovial fluid and serum markers for osteoarthritis in the horse receive:101658|
|Multiple Sclerosis and Related Disorders||Interleukin 1 receptor antagonist and 2′-5′-oligoadenylate synthetase-like molecules as novel biomarkers for multiple sclerosis patients in Bahrain pubmed:29141788|
|Advances in Medical Sciences||A similar pro/anti-inflammatory cytokine balance is present in the airways of competitive athletes and non-exercising asthmatics pubmed:28822267|